A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3089-3093

  Lim, S M ^a   Chang, H ^b   Yoon, M J ^a   Hong, Y K ^c   Kim, H ^a   Chung, W Y ^a   Park, C S ^a   Nam, K H ^a   Kang, S W ^a   Kim, M K ^d   Kim, B S ^e   Lee, S H ^f   Kim, H G ^g   Na, I I ^h   Kim, Y S ⁱ   Choi, M Y ^j   Kim, J G ^k   Park, K U ^l   Yun, H J ^m   Kim, J H ^a   Cho, Byoung C ^a,n   more..

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c JE UK Institute of Cancer Research   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Asan Medical Center   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Gyeongsang National University School of Medicine   (South Korea)

^h Korea Cancer Center Hospital   (South Korea)

ⁱ Kosin University   (South Korea)

^j Inje University College of Medicine   (South Korea)

^k Kyungpook National University Hospital   (South Korea)

^l Dongsan Medical Center   (South Korea)

^m Chungnam National University College of Medicine   (South Korea)

ⁿ Yonsei University College of Medicine   (South Korea)

more..

Author keywords

Efficacy; Everolimus; mTOR inhibitor; Safety; Thyroid cancer

Indexed keywords

CALCITONIN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE ISOENZYME; IODINE 131; PACLITAXEL; THYROGLOBULIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE PYELONEPHRITIS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANAPLASTIC THYROID CANCER; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIFFERENTIATED THYROID CANCER; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; INTERSTITIAL PNEUMONIA; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POORLY DIFFERENTIATED THYROID CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; WESTERN BLOTTING;

EFFICACY; EVEROLIMUS; MTOR INHIBITOR; SAFETY; THYROID CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; SIROLIMUS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84888811206     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt379     Document Type: Article

References (20)

1. Sherman SI. Thyroid carcinoma. Lancet 2003; 361: 501-511.
2. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol 2010; 22: 464-468.
3. Leboullex S, Baudin E, Travagli JP et al. Medullary thyroid carcinoma. Clin Endocrinol 2004; 61: 299-310.
4. Lim SM, Shin SJ, Chung WY et al. Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012; 53: 352-357.
5. Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26: 4708-4713.
6. Sherman SI, Wirth LJ, Droz JP et al. Mosetanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-34.
7. Gupta-Abramson V, Troxel BT, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 28: 4714-4719.
8. Cohen EE, Needles BM, Cullen KJ et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008; 26: 4708-4713.
9. Wells SA, Jr, Gosnell JE, Gagel RF et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767-772.
10. Tamburrino A, Molinolo AA, Salerno P et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin Cancer Res 2012; 18: 3532-3540.
11. Souza EC, Ferreira AC, Carvalho DP. The mTOR protein as a target in thyroid cancer. Expert Opin Ther Targets 2011; 15: 1099-1112.
12. Liu D, Hou P, Liu Z et al. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009; 69: 7311-7319.
13. Kouvaraki MA, Liakou C, Paraschi A et al. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery 2011; 150: 1258-1265.
14. Faggiano A, Ramundo V, Dicitore A et al. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med 2012; 16: 1563-1572.
15. Jin N, Jiang T, Rosen DM et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009; 10: 4107-4112.
16. Benjamin D, Colombi M, Moroni C et al. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10: 868-880.
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline. Eur J Cancer 2009; 45: 228-247.
18. Tarhini A, Kotsakis A, Gooding W et al. Phase II study of everolimus in previously treated small cell lung cancer. Clin Cancer Res 2010; 16: 5900-5907.
19. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 9: 449-456.
20. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.